CRMD
CorMedix Inc.
Healthcare — Biotechnology
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
Buy
1.6 / 5
5 analysts
$7.42
$-0.28 (-3.64%)
Target:
$15.20
(104.9%)
Price History
52-Week Range
Sign in to add CRMD to a watchlist or set price alerts.
Fundamentals
| Market Cap | $664.49M |
| P/E Ratio (TTM) | 3.90 |
| Forward P/E | 24.20 |
| EPS (TTM) | $2.17 |
| Dividend Yield | - |
| Profit Margin | 45.25% |
| Revenue Growth | 226.10% |
| ROE | 65.59% |
| Debt/Equity | 33.73 |
| Recommendation | Buy 1.6 |
| Analyst Target | $15.20 |
| Analysts | 5 |
| Next Earnings | Aug 13, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 45.1 |
| Beta | 1.47 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $14.96 |
| 52-Week Low | $6.13 |
| 50-Day Avg | $8.08 |
| 200-Day Avg | $8.97 |
| Avg Volume | $1.27M |
| Volume | 857.2K |
Performance Analysis
BULLISHCRMD shows predominantly bullish signals based on its fundamentals and technicals.
~
Trading at 15% of its 52-week range.
~
RSI at 45.1 is in neutral territory.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
+
P/E of 3.9 suggests the stock may be undervalued.
+
Strong revenue growth of 226.1% year-over-year.
+
Healthy profit margin of 45.2%.
+
Wall Street consensus is "Buy" from 5 analysts.
+
Average analyst target of $15.20 implies 104.9% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:04 UTC
Back to Screener Export Report